Position statement on radiopharmaceutical production for clinical trials

Springer Science and Business Media LLC - Tập 2 Số 1 - 2017
Guy Bormans1, Andreas K. Buck2, Arturo Chiti3, Mandelin Cooper4, Jilly Croasdale5, Marie-Dominique Desruet6, Vikas Kumar7, Y. Liu8, Iván Peñuelas9, Claudio Rossetti10, Riccardo Schiavo11, Sally W. Schwarz12, Albert D. Windhorst13
1Radiopharmaceutical Research KU Leuven, Leuven, Belgium
2University of Wurzburg, Würzburg, Germany
3Humanitas University and Humanitas Research Hospital, Milan, Italy
4Royal Liverpool University Hospital, Liverpool, UK
5Sandwell & West Birmingham Hospitals NHS Trust, Birmingham, UK
6Hospital Grenoble-Alpes, La Tronche, France
7Sydney Medical School, Sydney University, Camperdown, Australia
8European Organisation for Research and Treatment of Cancer (EORTC)Brussels Belgium
9ClínicaUniversidad de Navarra, Pamplona, Spain
10Ospedale Niguarda, Milan, Italy
11Ospedale Belcolle, Viterbo, Italy
12Washington University School of Medicine. St. Louis, Mo. USA
13VU University Medical Center, Amsterdam, The Netherlands

Tóm tắt

Từ khóa


Tài liệu tham khảo

Decristoforo C, Penuelas I, Elsinga P, et al. Radiopharmaceuticals are special, but is this recognized? The possible impact of the new clinical trials regulation on the preparation of radiopharmaceuticals. Eur J Nucl Med Mol Imaging. 2014;41(11):2005–7.

Official Journal of European Union, 27/5/2014 L158/1–74.

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Tập 2 Số 1

Thông tin tác giả